K Lakota1,2, K Perdan-Pirkmajer3, S Sodin-Šemrl3,4, S Čučnik3,5, V Šubelj6, K Prosenc6, K Mrak Poljšak3, M Tomšič3,7, A Ambrožič3, S Praprotnik3. 1. Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia. katja.lakota@guest.arnes.si. 2. Faculty of Mathematics, Natural Science and Information Technologies, University of Primorska, 6000, Koper, Slovenia. katja.lakota@guest.arnes.si. 3. Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia. 4. Faculty of Mathematics, Natural Science and Information Technologies, University of Primorska, 6000, Koper, Slovenia. 5. Chair of Pharmacy, University of Ljubljana, 1000, Ljubljana, Slovenia. 6. Laboratory for public health virology, National Laboratory for Health, Environment and Food, Ljubljana, 1000, Slovenia. 7. Faculty of Medicine, University of Ljubljana, 1000, Ljubljana, Slovenia.
Abstract
INTRODUCTION: Influenza may cause severe complications in patients with autoimmune inflammatory rheumatic disease (AIRD), to whom vaccinations are especially recommended. However, AIRD patients require cautious scrutiny of immunogenicity as they might exhibit poor antibody response to vaccination, especially when taking immunomodulatory medications. AIM: The aim was to determine immunogenicity of seasonal and pandemic influenza vaccine in AIRD patients, its timeline/persistence, and influence of medications on immune response. METHODS: One hundred and thirty-seven AIRD and 54 healthy controls were vaccinated with trivalent seasonal influenza. After 3-5 weeks, 15 healthy controls and 93 AIRD were vaccinated with pandemic influenza vaccine, and 63 of patients were vaccinated a second time after 3-5 weeks. Sera were collected before vaccination, 18-90 days after each vaccination, and more than 180 days after the last vaccination. The immune response was measured using hemagglutination inhibition (HI) assay and IgG/IgA antibodies against influenza A/B with ELISA. RESULTS: Our findings indicate that following vaccination with seasonal influenza vaccine, seroprotection, seroresponse, and change in geometric mean titers (GMT) in AIRD patients was not compromised compared to healthy. Similarly, we report for pandemic influenza vaccination little added benefit of the second dose. We confirm lowest increase in HI titer in rituximab-treated AIRD compared to other medications. Vaccination largely tilts the balance from negative ELISA A IgG and IgA titers to positive titers in seasonal H1N1 seroresponsive AIRD patients and controls. A significant decrease in HI GMT and seroprotection was observed only in AIRD at > 180 days after vaccination highlighting an absent persistence of immunogenic response in AIRD patients. Due to high initial HI titers for influenza vaccine, we foresee their benefit in personalized medicine in the future. CONCLUSION: Influenza vaccination is immunologically active for AIRD, with little value of the second dose of the pandemic vaccine and further scrutiny on persistence of immune response to vaccine in AIRD is needed.
INTRODUCTION: Influenza may cause severe complications in patients with autoimmune inflammatory rheumatic disease (AIRD), to whom vaccinations are especially recommended. However, AIRD patients require cautious scrutiny of immunogenicity as they might exhibit poor antibody response to vaccination, especially when taking immunomodulatory medications. AIM: The aim was to determine immunogenicity of seasonal and pandemic influenza vaccine in AIRD patients, its timeline/persistence, and influence of medications on immune response. METHODS: One hundred and thirty-seven AIRD and 54 healthy controls were vaccinated with trivalent seasonal influenza. After 3-5 weeks, 15 healthy controls and 93 AIRD were vaccinated with pandemic influenza vaccine, and 63 of patients were vaccinated a second time after 3-5 weeks. Sera were collected before vaccination, 18-90 days after each vaccination, and more than 180 days after the last vaccination. The immune response was measured using hemagglutination inhibition (HI) assay and IgG/IgA antibodies against influenza A/B with ELISA. RESULTS: Our findings indicate that following vaccination with seasonal influenza vaccine, seroprotection, seroresponse, and change in geometric mean titers (GMT) in AIRD patients was not compromised compared to healthy. Similarly, we report for pandemic influenza vaccination little added benefit of the second dose. We confirm lowest increase in HI titer in rituximab-treated AIRD compared to other medications. Vaccination largely tilts the balance from negative ELISA A IgG and IgA titers to positive titers in seasonal H1N1 seroresponsive AIRD patients and controls. A significant decrease in HI GMT and seroprotection was observed only in AIRD at > 180 days after vaccination highlighting an absent persistence of immunogenic response in AIRD patients. Due to high initial HI titers for influenza vaccine, we foresee their benefit in personalized medicine in the future. CONCLUSION: Influenza vaccination is immunologically active for AIRD, with little value of the second dose of the pandemic vaccine and further scrutiny on persistence of immune response to vaccine in AIRD is needed.
Authors: Nicole Harrison; Wolfgang Poeppl; Manuel Miksch; Klaus Machold; Hans Kiener; Daniel Aletaha; Josef S Smolen; Christina Forstner; Heinz Burgmann; Heimo Lagler Journal: Vaccine Date: 2018-07-03 Impact factor: 3.641
Authors: S van Assen; N Agmon-Levin; O Elkayam; R Cervera; M F Doran; M Dougados; P Emery; P Geborek; J P A Ioannidis; D R W Jayne; C G M Kallenberg; U Müller-Ladner; Y Shoenfeld; L Stojanovich; G Valesini; N M Wulffraat; M Bijl Journal: Ann Rheum Dis Date: 2010-12-03 Impact factor: 19.103
Authors: K Perdan-Pirkmajer; G G Thallinger; N Snoj; S Čučnik; P Žigon; T Kveder; D Logar; S Praprotnik; M Tomšič; S Sodin-Semrl; A Ambrožič Journal: Lupus Date: 2012-02 Impact factor: 2.911
Authors: Suzanne E Ohmit; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Arnold S Monto Journal: J Infect Dis Date: 2011-10-12 Impact factor: 5.226
Authors: F Atzeni; K Bendtzen; F Bobbio-Pallavicini; F Conti; M Cutolo; C Montecucco; A Sulli; G Valesini; P Sarzi-Puttini Journal: Clin Exp Rheumatol Date: 2008 Jan-Feb Impact factor: 4.473